Clear All
777 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
C9257 Bevacizumab Avastin 0.25 mg Immunotherapy Monoclonal Antibody VEGFR No 2004 Jan 1, 2010 In Use
NA Finasteride Proscar 5mg Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Yes 1992 In Use
NA Metoclopramide Reglan 5mg, 10mg Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Yes 1991 In Use
Q5115 Rituximab-abbs Truxima 10mg Immunotherapy Monoclonal Antibody CD20 No 2018 Jul 1, 2019 In Use
J1456 Fosaprepitant (Teva) Fosaprepitant (Teva) 1mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 No 2019 Dec 21, 2022 In Use
J8565 Gefitinib Iressa 250 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2015 Jan 1, 2005 In Use
J9352 Trabectedin Yondelis 0.1mg Chemotherapy Alkylating Agent Natural Product No 2015 Jan 1, 2017 In Use
J9355 Trastuzumab Herceptin 10 mg Immunotherapy Monoclonal Antibody HER2 No 1998 Jan 1, 2000 In Use
NA Pilocarpine Hydrochloride Pilocarpine 5mg, 10mg Ancillary Therapy Miscellaneous Agent Cholinergic Agent Yes 2020 In Use
Revumenib Revuforj 25mg, 110mg, 160mg Chemotherapy Enzyme Inhibitor KMT2A Yes 2024 In Use
NA Ripretinib Qinlock 50mg Chemotherapy Tyrosine Kinase Inhibitor KIT, PDGFRA Yes 2020 In Use
NA Binimetinib Mektovi 15mg Chemotherapy MEK Inhibitor MEK 1/2 Yes 2018 In Use
J0881 Darbepoetin alfa Aranesp 1 mcg Ancillary Therapy Erythropoiesis-Stimulating Agent No 2001 Jan 1, 2006 In Use
J9264 Paclitaxel Abraxane, protein bound 1 mg Chemotherapy Antimitotic Agent Taxane No 1992 Jan 1, 2006 In Use
Q5120 Pegfilgratim-bmez Ziextenzo 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony Stimulating Factor No 2019 Jul 1, 2020 In Use
Q5127 Pegflilgrastim-fpgk Stimufend 0.5mg Ancillary Therapy Immunostimulant Granulocyte colony stimulating factor No 2022 Mar 17, 2023 In Use
NA Selumetinib Koselugo 10mg, 25mg Chemotherapy MEK Inhibitor MEK 1/2 Yes 2020 In Use
A9607 Lutetium Lu 177 vipivotide tetraxetan PLUVICTO 1 millicurie Radiopharmaceutical Radiopharmaceutical In Use
J9350 Mosunetuzumab-axgb Lunsumio 1mg Immunotherapy Monoclonal Antibody CD20, CD3 No 2022 Jul 11, 2023 In Use
NA Rucaparib Rubraca 200 mg Chemotherapy Enzyme Inhibitor PARP Yes 2017 In Use
NA Ruxolitinib Jakafi 10 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
J9380 Teclistamab cqyv Tecvayli 0.5mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2022 Jul 11, 2023 In Use
J3315 Triptorelin Pamoate Trelstar, Trelstar Mixject 3.75 mg Hormonal Therapy GnRH Agonist No 2000 Jan 1, 2003 In Use
Vorasidenib Voranigo 10mg,40mg Chemotherapy IDH Inhibitor IDH1, IDH2 Yes 2024 In Use
J9055 Cetuximab Erbitux 10 mg Immunotherapy Monoclonal Antibody EGFR No 2004 Jan 1, 2005 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.